Innovating Immunity
Modulating the immune system to advance new therapeutic discoveries, fast-track drug development and improve patient quality of life.
Our Mission
We are building an innovative product pipeline of immunotherapies focused in the therapeutic areas of Cancer, Autoimmune Diseases and Chronic Inflammation. Our mission is to deliver orally administered medicines that make a real difference in quality of life for our patients.
Pipeline in a molecule
Our strategic “Pipeline in a molecule” R&D approach is to advance each clinical candidate compound that has been target-validated in several preclinical Proof of Concept disease models to enter into parallel clinical development across multiple disease indications. One Drug: Multiple INDs & NDA Approvals.
Structure-guided drug design
Innovimmune discovers and develops its proprietary New Chemical Entity (NCE) pipeline of oral small-molecule medicines with computational machine learning and AI. Using structure-guided drug design coupled with fragment-based drug design, we develop new drugs by enabling intractable disease-associated proteins to become druggable therapeutic targets.
Our latest news
Take a look through the development of our latest technology.
Meet with us
Take a look through our upcoming events.
About us
Innovimmune is a privately-held Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule New Chemical Entity (NCE) immunomodulatory drugs for the treatment of Cancer, Autoimmune Diseases & Chronic Inflammation. We have assembled a world-class team of life science industry R&D veterans and are collaborating with medical thought leaders in renowned academic institutions.